1
|
Salcius M, Bauer AJ, Hao Q, Li S, Tutter A, Raphael J, Jahnke W, Rondeau JM, Bourgier E, Tallarico J, Michaud GA. SEC-TID: A Label-Free Method for Small-Molecule Target Identification. ACTA ACUST UNITED AC 2014; 19:917-27. [PMID: 24554445 DOI: 10.1177/1087057114522691] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/01/2013] [Accepted: 01/08/2014] [Indexed: 11/16/2022]
Abstract
Bioactive small molecules are an invaluable source of therapeutics and chemical probes for exploring biological pathways. Yet, significant hurdles in drug discovery often come from lacking a comprehensive view of the target(s) for both early tool molecules and even late-stage drugs. To address this challenge, a method is provided that allows for assessing the interactions of small molecules with thousands of targets without any need to modify the small molecule of interest or attach any component to a surface. We describe size-exclusion chromatography for target identification (SEC-TID), a method for accurately and reproducibly detecting ligand-macromolecular interactions for small molecules targeting nucleic acid and several protein classes. We report the use of SEC-TID, with a library consisting of approximately 1000 purified proteins derived from the protein databank (PDB), to identify the efficacy targets tankyrase 1 and 2 for the Wnt inhibitor XAV939. In addition, we report novel interactions for the tumor-vascular disrupting agent vadimezan/ASA404 (interacting with farnesyl pyrophosphate synthase) and the diuretic mefruside (interacting with carbonic anhydrase XIII). We believe this method can dramatically enhance our understanding of the mechanism of action and potential liabilities for small molecules in drug discovery pipelines through comprehensive profiling of candidate druggable targets.
Collapse
Affiliation(s)
- Michael Salcius
- Developmental and Molecular Pathways Department, Novartis Institutes for Biomedical Research, Cambridge, MA, USA
| | - Andras J Bauer
- Developmental and Molecular Pathways Department, Novartis Institutes for Biomedical Research, Cambridge, MA, USA
| | - Qin Hao
- Analytical Sciences, Novartis Institutes for Biomedical Research, Cambridge, MA, USA
| | - Shu Li
- Analytical Sciences, Novartis Institutes for Biomedical Research, Cambridge, MA, USA
| | - Antonin Tutter
- Developmental and Molecular Pathways Department, Novartis Institutes for Biomedical Research, Cambridge, MA, USA
| | - Jacob Raphael
- Developmental and Molecular Pathways Department, Novartis Institutes for Biomedical Research, Cambridge, MA, USA
| | - Wolfgang Jahnke
- Center for Proteomic Chemistry, Novartis Institutes for Biomedical Research, Basel, Switzerland
| | - Jean-Michel Rondeau
- Center for Proteomic Chemistry, Novartis Institutes for Biomedical Research, Basel, Switzerland
| | - Emmanuelle Bourgier
- Center for Proteomic Chemistry, Novartis Institutes for Biomedical Research, Basel, Switzerland
| | - John Tallarico
- Developmental and Molecular Pathways Department, Novartis Institutes for Biomedical Research, Cambridge, MA, USA
| | - Gregory A Michaud
- Developmental and Molecular Pathways Department, Novartis Institutes for Biomedical Research, Cambridge, MA, USA
| |
Collapse
|